Omsan (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol (an estrogen) and levonorgestrel (a progestin) together suppress the hypothalamic‑pituitary‑ovarian axis, preventing the surge of luteinising hormone that triggers ovulation. The estrogen stabilises the endometrium, while the progestin thickens cervical mucus and alters the uterine lining, making it less receptive to sperm and implantation.

The dosing regimen for Omsan is determined by the prescribing healthcare professional. Typically, combined oral contraceptives are taken once daily at the same time for a 21‑day active phase followed by a hormone‑free interval, but the exact schedule should be confirmed with the prescriber.

Omsan is intended to prevent pregnancy and should not be used by women who are already pregnant. If pregnancy occurs, the medication must be stopped immediately. Regarding breastfeeding, combined oral contraceptives are generally considered compatible, but a healthcare provider should evaluate individual risk‑benefit factors.

To place an order, submit an enquiry on the Omsan product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Omsan contains the same estrogen‑progestin combination (ethinylestradiol and levonorgestrel) found in many other combined oral contraceptives. Its efficacy, safety profile and side‑effect spectrum are comparable to other products in this class, with differences mainly in dosage strengths, tablet size and brand‑specific excipients.

Omsan tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Omsan is taken orally, usually once daily with or without food. It is important to take the tablet at the same time each day to maintain consistent hormone levels. If a dose is missed, follow the specific guidance provided by the prescribing clinician or the product leaflet.

Serious but rare risks include venous thromboembolism, pulmonary embolism, stroke, myocardial infarction, and severe liver disease. Women with a history of clotting disorders, cardiovascular disease, smoking (especially over age 35), or certain cancers should discuss these risks with their healthcare provider before starting Omsan.

Omsan is contraindicated in women who are pregnant, have known or suspected breast cancer, have active liver disease, have a history of thromboembolic events, uncontrolled hypertension, or who are smokers over the age of 35. Anyone with a known hypersensitivity to ethinylestradiol, levonorgestrel, or any tablet excipients should also avoid using it.